Pymepharco Joint Stock Company Sustainability Profile
Pymepharco Joint Stock Company, commonly referred to as Pymepharco, is a prominent player in the pharmaceutical industry, headquartered in Vietnam. Established in 1997, the company has made significant strides in the production and distribution of high-quality pharmaceutical products across various regions, including the southern provinces of Vietnam. Specialising in the manufacture of generic medicines, Pymepharco is renowned for its commitment to quality and innovation. The company offers a diverse range of products, including prescription medications and over-the-counter solutions, which are distinguished by their efficacy and safety. With a strong market position, Pymepharco has achieved notable milestones, including certifications from international health authorities, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Pymepharco Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pymepharco Joint Stock Company's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pymepharco Joint Stock Company, headquartered in Vietnam, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of STADA Arzneimittel Aktiengesellschaft, which influences its climate commitments and initiatives. While no direct emissions data is available, Pymepharco's climate strategy is likely aligned with the broader sustainability goals set by its parent company, STADA Arzneimittel Aktiengesellschaft. This includes initiatives related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from STADA at a level 2 relationship. However, specific reduction targets or achievements have not been disclosed for Pymepharco. As a subsidiary, Pymepharco may benefit from STADA's established climate commitments, which could include efforts to reduce emissions across various scopes, although detailed information on these initiatives is not provided. The company is expected to adhere to industry-standard climate terminology and practices, reflecting a commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,639,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,032,800 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Pymepharco Joint Stock Company's Industry?
How Carbon Intensive is Pymepharco Joint Stock Company's Location?
Pymepharco Joint Stock Company's Scope 3 Categories Breakdown
Pymepharco Joint Stock Company's Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Top Scope 3 Categories
Pymepharco Joint Stock Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pymepharco Joint Stock Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
